文献速递系统性红斑狼疮

狼疮相关浆膜炎的复发风险与免疫抑制治疗:一项全国真实世界研究

Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study.
PubMed 文献 · RMD Open · 2026-05-13

初始抗炎治疗应答率87.1%,糖皮质激素使用与复发风险无关,传统免疫抑制剂未降低复发风险,而贝利尤单抗与较低复发风险相关(HR=0.34,95%CI 0.14-0.84;p=0.019)。

要点

  • 狼疮相关浆膜炎复发率高,46%患者经历至少1次复发。
  • 贝利尤单抗与较低浆膜炎复发风险相关(HR=0.34,95%CI 0.14-0.84)。
  • 传统免疫抑制剂(甲氨蝶呤、硫唑嘌呤、霉酚酸酯)未与复发风险降低相关。

核心结论

  • 在本全国队列中,贝利尤单抗而非传统免疫抑制剂与狼疮相关浆膜炎复发风险降低相关。

主要发现

  • 46%的患者经历至少1次复发。
  • 108/124(87.1%)可评估发作对初始抗炎治疗有应答,基于糖皮质激素的方案与阿司匹林/秋水仙碱方案之间无显著差异。
  • 糖皮质激素使用与复发风险增加无关(46.0% vs 46.2%,p=0.98)。
  • 传统免疫抑制剂(甲氨蝶呤、硫唑嘌呤、霉酚酸酯)与复发风险降低无关。
  • 贝利尤单抗与较低复发风险相关(HR=0.34,95%CI 0.14-0.84;p=0.019)。

关键数值与推荐

  • 初始应答定义为早期再评估时症状和体征消失。
  • 复发定义为指数发作后≥3个月需要强化治疗的再发。
  • 复发无生存率采用Kaplan-Meier法描述,并作为复发事件使用Prentice-Williams-Peterson gap-time Cox模型分析,校正预设混杂因素。

临床怎么用

  • 对于SLE相关浆膜炎患者,贝利尤单抗可能有助于降低复发风险,支持其进一步评估。
  • 传统免疫抑制剂在降低浆膜炎复发方面未显示获益,糖皮质激素使用未增加复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of systemic lupus erythematosus (SLE) is largely guided by organ involvement. Serositis affects up to 46% of patients, yet its treatment is mainly empirical and extrapolated from other manifestations, and long-term outcome data remain limited. We aimed to evaluate short-term response to anti-inflammatory therapy and to examine associations between immunosuppressive treatments and serositis relapse. METHODS: We conducted a multicentre retrospective real-world study in patients with SLE with pericarditis and/or pleuritis, identified through a nationwide call for case reporting. Initial response was defined as symptom and sign resolution at early reassessment. Relapse was defined as recurrence requiring treatment intensification ≥3 months after the index flare. Relapse-free survival was described by Kaplan-Meier methods and analysed as recurrent events using a Prentice-Williams-Peterson gap-time Cox model adjusted for prespecified confounders. RESULTS: One hundred patients contributed 180 serositis episodes (161 pericarditis, 51 pleuritis, associated in 32 cases) over a mean follow-up of 91 months; 46% experienced ≥1 relapse. Overall, 108/124 (87.1%) of evaluable episodes responded to initial anti-inflammatory therapy, with no significant difference between corticosteroid-based and aspirin/colchicine regimens. Corticosteroid use was not associated with increased relapse risk (46.0% vs 46.2%, p=0.98). Conventional immunosuppressants (methotrexate, azathioprine, mycophenolate mofetil) were not associated with reduced relapse risk, whereas belimumab was associated with lower relapse risk (HR=0.34, 95% CI 0.14 to 0.84; p=0.019). CONCLUSION: Lupus-related serositis is frequent and highly relapsing. In this national cohort, belimumab-but not conventional immunosuppressants-was associated with reduced serositis recurrence, supporting its further evaluation in lupus serositis.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Fels E, Goncalves C, Jousse-Joulin S, et al. Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study. RMD Open. 2026. PMID: 42128527. doi:10.1136/rmdopen-2026-006919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。